Taysha Gene Therapies, Inc. announced that on June 20, 2023, Paul B. Manning provided notice to the Board of his decision to resign from the Board and all committees thereof, effective immediately prior to the conclusion of the 2023 Annual Meeting in order to enable the Board to regain compliance with the majority independent board requirement of Nasdaq Listing Rule 5605(b)(1). Mr. Manning's resignation was not the result of any disagreement with the Company. Following his resignation, the Board appointed Mr. Manning as a non-voting board observer, and in such capacity, Mr. Manning may attend, in a non-voting capacity, all meetings of the Board.

Further, on June 21, 2023, the Board appointed Sean Stalfort to serve as a director of the Company, effective immediately following Mr. Manning's resignation. In doing so, the Board affirmatively determined that Mr. Stalfort is an independent director" within the meaning of the applicable Nasdaq listing standards. Mr. Stalfort will serve as a Class I director whose term will expire at the Company's 2024 annual meeting of stockholders.

The Board also appointed Mr. Stalfort to serve as chair of the Nominating and Corporate Governance Committee of the Board (the Nominating and Corporate Governance Committee") and a member of the Compensation Committee of the Board (the Compensation Committee"). There is no arrangement or understanding between Mr. Stalfort and any other person pursuant to which he was selected as a director of the Company, and there is no family relationship between Mr. Stalfort and any of the Company's other directors or executive officers. Sean Stalfort, age 53, is President of PBM Capital Group, LLC (PBM Capital"), a private equity and venture capital investment firm in the business of investing in healthcare and life-science related companies, and has worked at PBM Capital since 2010.

Mr. Stalfort currently serves on the boards of directors of Verrica Pharmaceuticals, Inc., a publicly-traded biopharmaceutical company, and Acumen Pharmaceuticals, Inc., a publicly-traded biopharmaceutical company. Additionally, he previously served as a member of the board of directors of Dova Pharmaceuticals, Inc., a publicly-traded biopharmaceutical company, from September 2016 to November 2019. Mr. Stalfort is also a founding partner of Octagon Partners LLC and Octagon Finance LLC, historic tax credit real estate companies.

Mr. Stalfort received a B.A. in business economics and political science from Brown University.